Multiple Myeloma

Sharing Markers with Patients

Jack Aiello talks about the importance of providers helping patients understand the value of markers and how that can positively affect the latter's compliance.
Video Library – February 5, 2016
Jack Aiello
Patient Advocate
San Jose, CA
Multiple myeloma survivor

I think it's really important for patients' treatment team to make sure they do stay on track with medications, and the way the treatment team helps ensure this is to share the information with the patient. How is the patient responding to treatment? How did the doctor know the patient is responding to treatment? The doctor is looking at certain markers.

Share those markers with a patient, so that the patients themselves knows what markers to follow and can understand what the doctor means when the doctor says, "Oh, you've achieved a very good response," or,"You've relapsed."

Those have clinical meanings that are important for patients to understand. When they begin to understand their treatment and the progress of their treatment, they tend to do a much better job of also being in charge of their own medications that they are taking, and become much more self‑aware of the importance of staying on those medications.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
By Jill Meyer-Lippert, RDH, Amanda Swiecichowski, RN, BSN, CHPN
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
FDA Approvals, News & UpdatesMultiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.